Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Change in Account Payables (2021 - 2025)

Prime Medicine's Change in Account Payables history spans 5 years, with the latest figure at -$581000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 123.62% year-over-year to -$581000.0; the TTM value through Dec 2025 reached $996000.0, up 118.95%, while the annual FY2025 figure was $996000.0, 118.95% up from the prior year.
  • Change in Account Payables reached -$581000.0 in Q4 2025 per PRME's latest filing, down from $3.0 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $5.8 million in Q3 2023 to a low of -$5.9 million in Q1 2024.
  • Average Change in Account Payables over 5 years is $436294.1, with a median of $1.0 million recorded in 2022.
  • Peak YoY movement for Change in Account Payables: surged 1535.66% in 2023, then crashed 1066.67% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at $80000.0 in 2021, then surged by 438.75% to $431000.0 in 2022, then surged by 428.77% to $2.3 million in 2023, then grew by 7.94% to $2.5 million in 2024, then plummeted by 123.62% to -$581000.0 in 2025.
  • Per Business Quant, the three most recent readings for PRME's Change in Account Payables are -$581000.0 (Q4 2025), $3.0 million (Q3 2025), and -$3.3 million (Q2 2025).